David Chu

David Chu, MD, PhD, currently serves as the Chief Medical Officer at Castle Creek Biosciences, Inc., since February 2025. Prior to this role, David Chu held several significant positions at Arcutis Biotherapeutics, Inc., including Vice President and Executive Director of Clinical Development from January 2021 to February 2025. David Chu has extensive experience in clinical development, having served as Director of Clinical Development in Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson from September 2019 to January 2021, and as Director of Contact Dermatitis in the Division of Dermatology at Scripps Clinic Medical Group from September 2009 to September 2019. David Chu's educational background includes a residency in Dermatology at NYU Grossman School of Medicine, an internship in Internal Medicine at Icahn School of Medicine at Mount Sinai, and an MD, PhD in Microbiology and Immunology from the University of California, San Francisco. David Chu also holds a Bachelor of Arts in Biochemical Sciences from Harvard University.